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Abstract 
Treatment of ocular cancers using eye plaque brachytherapy is now an established medical procedure. 
However, current QA for these eye plaques is quite rudimentary, limiting the opportunities for precise pre-
tumour plaque customisation. This paper proposes and experimentally validates a new technique for 
imaging of eye plaque dose distributions using a high-resolution pixelated silicon detector. Results are 
presented demonstrating the 2D and 3D isodose surfaces produced using experimental data collected 
using this method. 
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Abstract 
Treatment of ocular cancers using eye plaque brachytherapy is now an established medical procedure. However, current QA 
for these eye plaques is quite rudimentary, limiting the opportunities for precise per-tumour plaque customisation. This paper 
proposes and experimentally validates a new technique for imaging of eye plaque dose distributions using a high-resolution 
pixelated silicon detector. Results are presented demonstrating the 2D and 3D isodose surfaces produced using experimental 
data collected using this method. © 2001 Elsevier Science. All rights reserved 
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1.  Introduction  
Melanoma and squamous cell carcinoma are the 
most prevalent ocular malignancies in adults [1]. 
Disease morbidity and cost to the community is 
significant with almost 50% of patients losing vision 
or the eye due to the disease and/or the treatment 
[2,3]. Ocular melanoma is typically treated by 
resection of the surgical mass or for progressed 
tumours, via enucleation [4]. However, radiotherapy 
remains the most widely used treatment for posterior 
uveal melanoma, which carries a serious prognosis, 
especially if the tumour is medium or large in size 
[4]. Brachytherapy using radioactive eye plaques is 
the preferred method of treatment for patients with 
ocular malignancies.  
Eye brachytherapy involves the surgical insertion 
of a radioactive plaque behind the tumour residing 
within the eye of the patient. At present, the most 
popular eye plaques used for treating ocular cancers 
incorporate I-125 seeds or are uniformly coated with 
a radioactive material such as Ru106/ Rh106 [5].  
There are currently no procedures with the ability 
to provide quality assurance (QA) for customised 
plaques, taking into account factors such as tumour 
shape, location, and proximity to vital structures, 
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such as the optic nerve and macula which have been 
shown to receive up to 85% and 58% respectively of 
the prescribed dose during treatment[6]. This can 
result in optic neuropathy and macular degeneracy 
[7]. Furthermore, when the primary treatment fails to 
completely eradicate the tumour, the prognosis in 
terms of eye and sight preservation as well as 
survival becomes significantly reduced [4]. Overall, 
the failure rate after eye plaque brachytherapy is 
reported to be up to 10% and is a result of 
inaccuracies in dosage as well as the surgical 
placement of plaques [1].  
Experimental dosimetry in ocular radiotherapy, 
where tumours are small and can be close to critical 
structures such as the optical nerve, demands high 
spatial resolution dosimetry and high detector 
dynamic range due to the steep dose gradients 
involved. A new approach is required to provide real 
time, high spatial resolution, low dose rate dosimetry 
for eye plaque QA.  
QA of Ru-106 plaques using single fibre optic 
plastic scintillator dosimeters has previously been 
reported  [8, 9]. However, this requires a slow and 
complex scanning assembly to obtain 2D dose 
distributions and is limited in spatial resolution due 
by the size of the device (1.0x0.5mm) [8, 9]. 
Spectroscopic dosimetry, based on silicon radiation 
detectors, has been successfully used for point 
dosimetry in low dose rate brachytherapy utilising I-
125 seeds [10]. A pixelated, 2D array of such 
detectors, used in spectroscopy mode, is well suited 
for QA of eye plaque dosimetry. Silicon pixelated 
detectors such as the Medipix2 [11] and Timepix 
have been successfully used in radiography, 
neutronography, and micro-tomography [12] and are 
currently being investigated for eye plaque dosimetry 
at CMRP. These devices consist of an array of 
individual detectors (55x55µm pixels) [12]. Silicon 
pixelated detectors operating in spectroscopy mode 
can generate dosimetric images when placed below 
the treatment plaque within a phantom. The 
dosimetric images can be used to generate three-
dimensional dose functions with a high spatial 
resolution providing the desired dosimetric QA of the 
treatment prior to the procedure.  
2. Method  
The silicon pixelated detector, Medipix2, was used 
to obtain two dimensional dose distributions in 
several planes within a segmented 24mm diameter 
Perspex eye phantom. A 15mm ROPES stainless 
steel eye plaque, loaded with Oncura 6711 I-125 
based seeds, was attached to the phantom. Medipix2 
calibration was performed on the central axis of the 
phantom with a single I-125 seed and the TG-43 
protocol. Absolute calibration was conducted with 
one seed at depth 5mm. These results were compared 
with values predicted by the TG-43 treatment 
planning software (TPS) developed at CMRP to 
verify the dosimetry setup.  
Two seed configurations of the eye plaque were 
tested; an asymmetric 5 seed distribution, and a full 
10 seed distribution. Measurements at various planar 
angles were performed for the two seed 
configurations. With the plaque mounted on the top 
of the phantom, 2D dosimetric images were obtained 
using the Medipix2 at depths of 5, 10, 15, 20 and 
25mm from the surface of the eye phantom closest to 
the plaque and calibrated using the previous depth-
dose measurements. The 25 mm measurement was 
repeated with the plaque mounted at angles of 18º, 
45º, 75º, and 90º normal to Medipix2 plane. The 
resulting orthogonal and oblique 2D dosimetric 
images, with spatial resolution of 55um were used for 
reconstruction of 2D isodose lines and 3D isodose 
surfaces. 
3. Results  
The relative depth response of the Medipix2 was 
in agreement with the TG-43 depth dose distribution 
of a single seed to within 2%. Good conformity was 
achieved with the depth dose predicted by the TPS 
for this seed configuration of eye plaque.  
 
The depth planes measured by the detector can be 
seen in the left image of Figure 1 as a stack of 2D 
dosimetric images. The right hand image shows the 
calibrated isodose surfaces generated from the 2D 
dosimetric images. The 3D reconstruction of the 
series of planar angle dosimetric images can be seen 
in Figure 2. 
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Figure 1: Two dimensional measurements used to create isodose 
surfaces of plaque loaded with five I-125 seeds   
Figure 2: Reconstructed image using a number of two dimensional 
planar angles for 5 seeds plaque. 
4. Discussion  
The unique approach and system utilising 
pixelated detectors for fast, real time 3D dosimetric 
imaging for eye plaque QA will support the 
development of new medical procedures for the 
realisation of patient-specific plaques with the best 
customised dose distribution for each unique tumour. 
With a data acquisition time of just seconds and a 
high spatial resolution, this system overcomes many 
of the current limitations in dosimetry for clinical 
treatment, providing 3D dose imaging through the 
entire eye. This research provides significant 
evidence to suggest the feasibility of the 
customisation of eye plaques to optimise 
brachytherapy treatment of patients with eye 
melanomas as well as offering an accurate and real 
time QA system for treatment planning verification.  
An improved plaque-sensor distance control 
method is currently being evaluated at CMRP. The 
process involves the use of a linear actuator to control 
the plaque-detector distance within a liquid 
environment. 
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